AtriCure Stock Forecast, Price & News

+0.93 (+1.24 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume185,928 shs
Average Volume333,646 shs
Market Capitalization$3.48 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

AtriCure logo

About AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.10 out of 5 stars

Medical Sector

454th out of 1,352 stocks

Surgical & Medical Instruments Industry

43rd out of 123 stocks

Analyst Opinion: 2.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

Is AtriCure a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure
or view top-rated stocks.

What stocks does MarketBeat like better than AtriCure?

Wall Street analysts have given AtriCure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AtriCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AtriCure?

AtriCure saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 919,300 shares, a drop of 33.4% from the July 29th total of 1,380,000 shares. Based on an average daily trading volume, of 280,600 shares, the days-to-cover ratio is currently 3.3 days. Currently, 2.1% of the company's stock are sold short.
View AtriCure's Short Interest

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for AtriCure

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Tuesday, August, 3rd. The medical device company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.06. The medical device company earned $71.38 million during the quarter, compared to analyst estimates of $61.08 million. AtriCure had a negative trailing twelve-month return on equity of 10.18% and a negative net margin of 23.31%. AtriCure's revenue for the quarter was up 74.8% on a year-over-year basis. During the same period last year, the company posted ($0.38) EPS.
View AtriCure's earnings history

How has AtriCure's stock been impacted by Coronavirus (COVID-19)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC shares have increased by 114.9% and is now trading at $75.80.
View which stocks have been most impacted by COVID-19

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of $-1.200-$-1.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $-1.250. The company issued revenue guidance of $270 million-$275 million, compared to the consensus revenue estimate of $254.77 million.

What price target have analysts set for ATRC?

8 Wall Street analysts have issued 12 month price objectives for AtriCure's stock. Their forecasts range from $75.00 to $120.00. On average, they expect AtriCure's stock price to reach $89.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for AtriCure
or view top-rated stocks among Wall Street analysts.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.15%), BlackRock Inc. (8.03%), Alliancebernstein L.P. (6.21%), Invesco Ltd. (5.03%), Price T Rowe Associates Inc. MD (4.73%) and Champlain Investment Partners LLC (3.40%). Company insiders that own AtriCure stock include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends for AtriCure

Which major investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, FMR LLC, TimesSquare Capital Management LLC, Wasatch Advisors Inc., BlackRock Inc., Eagle Asset Management Inc., Neuberger Berman Group LLC, and Bellevue Group AG. Company insiders that have sold AtriCure company stock in the last year include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin, and Vinayak Doraiswamy.
View insider buying and selling activity for AtriCure
or view top insider-selling stocks.

Which major investors are buying AtriCure stock?

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Alliancebernstein L.P., Macquarie Group Ltd., Dimensional Fund Advisors LP, Thornburg Investment Management Inc., Principal Financial Group Inc., Castleark Management LLC, and Brinker Capital Investments LLC.
View insider buying and selling activity for AtriCure
or or view top insider-buying stocks.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $75.80.

How much money does AtriCure make?

AtriCure has a market capitalization of $3.48 billion and generates $206.53 million in revenue each year. The medical device company earns $-48,150,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 750 workers across the globe.

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART.

When was AtriCure founded?

AtriCure was founded in 2000.

What is AtriCure's official website?

The official website for AtriCure is

Where are AtriCure's headquarters?

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at (513) 755-4100.

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.